There have been upward revisions in current-year earnings estimates for Penumbra. The Zacks Consensus Estimate for the current year has surged 0.4% over the past month. While the overall earnings estimate revisions have made Penumbra a Zacks Rank #2 stock, it has earned itself a Growth Score of A based on a number of factors, including the ones discussed above. This combination positions Penumbra well for outperformance, so growth investors may want to bet on it. Growth stocks are attractive to many investo ...

Investor Relations Penumbra, Inc. [email protected] Source: Penumbra, Inc. Webcast & Conference Call Information Penumbra, Inc., headquartered in Alameda, California, is a global healthcare company focused on innovative therapies. Penumbra designs, develops, manufactures and markets novel products and has a broad portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries. For more in ...

Group 1 - Peninsula Energy is hosting a live virtual corporate update on July 9th, 2024, at 2:00pm ET, in collaboration with Red Cloud Financial Services [1][7] - The webinar will include a Q&A session moderated by Red Cloud, inviting shareholders and interested parties to participate [7] - Peninsula Energy is one of the few ASX-listed uranium companies with US production and market exposure, specifically through its Lance Projects in Wyoming [8] Group 2 - The Lance Projects are set to resume production in December 2024 after a capacity expansion of the central processing plant [8] - Peninsula Energy has established a strong track record of meeting delivery requirements since 2016, with 10 years of sales contracts in place with major utilities in the US and Europe [8] - Once production resumes, Peninsula Energy aims to become a fully independent end-to-end producer of yellowcake, positioning itself as a key supplier of uranium in the clean energy sector [8]

PEN is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. Additionally, the company could be a top pick for growth investors. PEN has a Growth Style Score of A, forecasting year-over-year earnings growth of 37.3% for the current fiscal year. Five analysts revised their earnings estimate higher in the last 60 days for fiscal 2024, while the Zacks Consensus Estimate has increased $0.02 to $2.87 per share. PEN also boasts an average earnings surprise of 26%. With a solid Zacks Rank and top-tier Growth and V ...

It has been about a month since the last earnings report for Penumbra (PEN) . Shares have lost about 4.8% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Penumbra due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Penumbra Q1 Earnings Miss, Margins Improve Penumbr ...

ALAMEDA, Calif., June 4, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024. Event: Truist Securities MedTech Conference Date: Tuesday, June 18, 2024 Time: 10:05am ET/7:05am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on the com ...

ALAMEDA, Calif., May 23, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the William Blair Growth Stock Conference on Thursday, June 6, 2024. Event: William Blair Growth Stock Conference Date: Thursday, June 6, 2024 Time: 12:20pm ET/9:20am PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on the c ...

Penumbra, Inc. (NYSE:PEN) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - President, Chairman and CEO Maggie Yuen - CFO Jason Mills - Executive Vice President of Strategy Conference Call Participants Margaret Kaczor - William Blair Joanne Wuensch - Citi William Plovanic - Canaccord Genuity Fund Robert Marcus - JPMorgan Larry Biegelsen - Wells Fargo Matthew O'Brien - Piper Sandler Michael Sa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____ to _____ Commission File Number: 001-37557 Penumbra, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpor ...

Exhibit 99.1 Penumbra, Inc. Reports First Quarter 2024 Financial Results ALAMEDA, Calif., May 7, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Total revenue increased to $278.7 million for the first quarter of 2024 compared to $241.4 million for the first quarter of 2023, an increase of 15.4%, or 15.2% in constant currency . The Uni ...